Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis
- 755 Downloads
A total of 177 patients with moderate-to-severe hip or knee osteoarthritis (OA) were tested over a period of 26 weeks in a two-center, two-armed, randomized, double-blind, comparison study. The aim was to see if a combination of glucosamine sulfate (1500 mg/day) and the omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (group A), showed equivalence (noninferiority) or superiority as opposed to glucosamine sulfate alone (group B).
The primary therapy evaluation was performed using the Western Ontario and McMaster Universities Arthrosis index (WOMAC) score. At the end of the study, a reduction in the pain score of ≥20% was required (primary target criterion) and the quantitative difference in the WOMAC subscores pain, stiffness, and function were analyzed (secondary target criteria).
Results and Conclusion
When a minimal pain reduction of ≥20% was chosen, there was no statistically significant difference in the number of responders between the two groups (92.2% group A, 94.3% group B). A higher responder criterion (≥80% reduction in the WOMAC pain score) was chosen. Therefore, the frequency of responders showed a therapeutic and statistical superiority for the combination product of glucosamine sulfate and the omega-3 polyunsaturated fatty acids in patients who complied with the study protocol (group A 44%, group B 32%; P=0.044). OA symptoms (morning stiffness, pain in hips and knees) were reduced at the end of the study: by 48.5%–55.6% in group A and by 41.7%–55.3% in group B. The reduction was greater in group A than in group B. There was a tendency toward superiority shown in the secondary target criteria and concurrent variables. In the global safety evaluation, both products have been demonstrated to be very safe in long-term treatment over 26 weeks. To our knowledge, this is the first clinical trial in which glucosamine was given in combination with omega-3 fatty acids to patients with OA.
Keywordscomparison study docosahexaenoic acid double-blind eicosapentaenoic acid glucosamine sulfate omega-3 fatty acids osteoarthritis randomized WOMAC
- 2.Baker CL Jr, Ferguson CM. Future treatment of osteoarthritis. Orthopedics. 2005;28(suppl. 2):227–234.Google Scholar
- 8.Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2008;CD002946.Google Scholar
- 9.Kim JJ, Conrad HE. Effect of D-glucosamine concentration on the kinetics of mucopolysaccharide biosynthesis in cultured chick embryo vertebral cartilage. J Biol Chem. 1974;249:p3091–3097.Google Scholar
- 13.Förster K, Reichelt A. Gonarthrose - Aktuelle Aspekte in der Therapie mit Glucosaminsulfat (dona 200-S). Fortsch Med. 1998;116(suppl. 183):1–12.Google Scholar
- 15.Müller-Faßbender H, Bach G. D-Glucosamine-sulfate als nebenwirkungsarme alternative zu nichtsteroidalen antirheumatika. In: Bach G, Stock K, editors. Aktuelle Rheumatologie Bayreuth-Pathologie-Labor-Untersuchung-Therapie 1989. Köln: Echo Verlags-GmbH; 1990;109–124.Google Scholar
- 22.Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(suppl. 6):1505–1519.Google Scholar
- 30.European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit (EMEA). Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. 1998;CPMP/EWP/784/97:1–7. Available at: www.emea.europa.eu/pdfs/human/ewp/078497en.pdf. Accessed August 4, 2009.Google Scholar
- 33.MacLean CH, Mojica WA, Morton SC, et al. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ). 2004;(89):1–4.Google Scholar